Canadian Governments Move To Normalize Psychedelic Therapy Progress towards normalizing psychedelic therapies has been made by the Canadian government with its recent move to authorize physicians to prescribe medicinal psychedelic drug treatments.
This amendment to Health Canada’s Special Access Program expands access to MDMA and psilocybin therapy, just as has been done with ketamine therapy.
This is big news for the industry. As the validity of these therapies continues to be explored and data collected, there will be an ever-growing chance for psychedelic companies to capitalize on the $80 billion spent by the Canadian social and healthcare system annually.
The unique investment platform Origin Therapeutics aims to offer a breadth of exposure to the psychedelics industry, with investment into both private and public companies. The majority of the companies Origin invests in would normally only be available to venture capitalists and angel investors. The fund is expected to IPO under $ORIG on the CSE.
Recently, one of Origin’s portfolio companies Microdose Psychadelic Insights completed a strong 2021. Its Q4 revenue hit $1.4 million (CAD), which increased its year one guidance by more than 23% to $3.7 million, putting it on track for profitability by Q3 of 2022.
https://originpsychedelics.com/newsroom/origin-therapeutics-applauds-health-canada-amendment-of-special-access-program-for-psychedelics/